Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx, Pharmacia to Strike 3-D Proteomics Collaboration

NEW YORK, Jan. 23 - Drug-discovery company Syrrx is set to announce a collaboration with Pharmacia to determine the 3-D structure of proteins that may provide future drug targets.

 

The two firms will focus on drugs to treat cancer, inflammation, infectious disease, among other disorders. Under the agreement, Pharmacia will pay a technology access fee, R&D funding, and success payments. The pharmaceutical company may also take an equity stake in Syrrx.

 

Financial details of the agreement, which will be announced on Thursday, were not revealed.

 

Pharmacia also plans to deploy Syrrx's technology platform internally, where it is expected to improve and streamline the effort to ascertain protein structures. Syrrx's technologies are designed to speed the labor-intensive process of x-ray crystallography.

 

According to Syrrx CEO Wendell Wierenga, the effort is the first large-scale, multi-family structural proteomics effort adopted by a major pharmaceutical company.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.